HPRHealth Psychology ResearchTBA2420-8124Health Psychology Research10.52965/001c.38930GeneralPhenothiazines and their Evolving Roles in Clinical Practice: A   Narrative Reviewhttps://healthpr.org/journal/HPR/10/4/10.52965/001c.38930N. EdinofAmber,ArmisteadGrace,A RosaChristina,AndersonAlexandra,PatilRonan,CornettElyse M,S. MurnaneKevin,M. KayeAdam,D. KayeAlan20221042022-11-02Phenothiazines, a diverse class of drugs, can be used to treat multiple mental health and physical conditions. Phenothiazines have been used for decades to treat mental illnesses, including schizophrenia, mania in bipolar disorder, and psychosis. Additionally, these drugs offer relief for physical illnesses, including migraines, hiccups, nausea, and vomiting in both adults and children. Further research is needed to prove the efficacy of phenothiazines in treating physical symptoms. Phenothiazines are dopaminergic antagonists that inhibit D2 receptors with varying potency. High potency phenothiazines such as perphenazine are used to treat various psychiatric conditions such as the positive symptoms of schizophrenia, the symptoms of psychosis, and mania that can occur with bipolar disorder. Low/mid potency phenothiazines such as chlorpromazine antipsychotic drugs that have been used to treat schizophrenia and schizophrenia-like disorders since the 1950s and are utilized in numerous disease states. The present investigation aims to elucidate the effects of phenothiazines in clinical practice.Phenothiazines, chlorpromazine, perphenazine, migraines, hiccups, nausea and vomiting, adverse effects

1. Kidron A, Nguyen H. Phenothiazine. In: StatPearls. StatPearls Publishing; 2022. Accessed February 26, 2022. http://www.ncbi.nlm.nih.gov/books/NBK55611/3/2. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.3. Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47(13):2217-2228. doi:10.1017/s0033291717000873 4. Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018;(2):CD000459. doi:10.1002/14651858.cd000459.pub3 5. Adams CE, Eisenbruch M. Depot fluphenazine for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000307. doi:10.1002/14651858.cd000307 6. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology. 1981;73(3):205-210. doi:10.1007/bf00422403 7. Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA. Fluphenazine decanoate and tardive dyskinesia: a possible association. Am J Psychiatry. 1981;138(10):1362-1365. doi:10.1176/ajp.138.10.1362 8. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016;39(6):509-516. doi:10.1007/s40264-016-0398-9 9. Laborit H, Huguenard P. Artificial hibernation by pharmacodynamical and physical means. Presse Med. 1951;59(64):1329. 10. Davis JM, Garver DL. Neuroleptics: Clinical Use in Psychiatry. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology. Vol 10. Springer US; 1978:129-164. doi:10.1007/978-1-4613-4042-3_4 11. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014;(1):CD000284. doi:10.1002/14651858.cd000284.pub3 12. Martindale W, Parfitt K. The Complete Drug Reference. Pharmaceutical Press; 1999. Accessed May 27, 2021. http://archive.org/details/martindale00kath 13. O’Reilly PO, Wojcicki HM, Hrychuk W, Keogh RP. Perphenazine (Trilafon) Treatment of Psychoses. Can Med Assoc J. 1957;77(10):952-955. 14. Hartung B, Sampson S, Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst Rev. 2015;(3):CD003443. doi:10.1002/14651858.cd003443.pub3 15. Woelk CJ. Managing hiccups. Can Fam Physician. 2011;57(6):672-675. 16. Friedgood CE, Ripstein CB. Chlorpromazine (thorazine) in the treatment of intractable hiccups. J Am Med Assoc. 1955;157(4):309-310. doi:10.1001/jama.1955.02950210005002 17. Williamson BW, MacIntyre IM. Management of intractable hiccup. Br Med J. 1977;2(6085):501-503. doi:10.1136/bmj.2.6085.501 18. Long B, Koyfman A, Gottlieb M. Prochlorperazine for Treatment of Acute Migraines in Adults. Acad Emerg Med. 2020;27(3):243-244. doi:10.1111/acem.13864 19. Otręba M, Kośmider L, Rzepecka-Stojko A. Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review. Eur J Pharmacol. 2020;887:173553. doi:10.1016/j.ejphar.2020.173553 20. McGee JL, Alexander MR. Phenothiazine analgesia--fact or fantasy? Am J Hosp Pharm. 1979;36(5):633-640. 21. Windgassen KW, Wesselmann U, Schulze Mönking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 1996;33(3):142-146. doi:10.1159/000119265 22. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(Suppl 8):5-11; discussion 12-13. 23. Diogo Telles-Correia A, nio Barbosa HCP, Machado R. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26-38. doi:10.4292/wjgpt.v8.i1.26 24. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25(6):473-490. doi:10.2165/11587800-000000000-00000 25. Sicouri S, Antzelevitch C, Lankenau Institute for Medical Research, Wynnewood, PA, USA, Lankenau Institute for Medical Research, Wynnewood, PA, USA, Lankenau Heart Institute, Wynnewood, PA, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol Rev. 2018;7(3):199. doi:10.15420/aer.2018.29.2 26. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992;11(10):851-856. 27. Jibson MD. First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. UpToDate. Published online June 2021. 28. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23(S1):S27-S41. doi:10.1002/hup.917 29. Lovell CR, Cronin E, Rhodes EL. Photocontact urticaria from chlorpromazine. Contact Dermatitis. 1986;14(5):290-291. doi:10.1111/j.1600-0536.1986.tb05278.x